Catalyst
Slingshot members are tracking this event:
Phase 1 pegilodecakin (PEG-rhuIL-10) combination with anti-PD-1 antibodies, and combination with FOLFOX in renal cell carcinoma, pancreatic cancer, and non-small cell lung cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ARMO |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 11, 2018
Occurred Source:
https://www.mdedge.com/oncologypractice/article/156109/renal-cell-carcinoma/phase-1-study-human-il-10-plus-checkpoint
Related Projects
- Discussing the NSCLC landscape after KEYNOTE-189 data, specifically PD-1 combo programs MRK, ARMO, NKTR Executed On: Apr 30, 2018 at 10:00 AM EDT
Related Keywords
Pegilodecakin, Interlekin, Cytokines, Il-10, Pd-1, Cancer Immunotherapy, Checkpoint Inhibitor, Pancreatic Cancer, Pdac, Nsclc, Rcc, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Folfox
